Pfizer Stock Price Forecast - PFE Shares Reclaims Investor Confidence With Metsera Buyout

Pfizer Stock Price Forecast - (NYSE:PFE) Rebuilds Growth Momentum Through Metsera Acquisition, Oncology Expansion, And Deep Cost Cuts

Pfizer Inc. (NYSE:PFE) is trading around $25.74 per share, with a market capitalization of roughly $146 billion, signaling that Wall Street continues to undervalue one of the most cash-generative pharmaceutical firms globally. Despite losing more than half of its market value since its pandemic peak, the company’s turnaround strategy is now visibly taking shape. Pfizer’s Q3 2025 results showed that its restructuring efforts are driving real operational efficiency. Revenue came in at $16.65 billion, beating expectations by $150 million, while earnings per share of $0.87 surpassed analyst forecasts by $0.23. The firm maintained its full-year guidance of $61 billion–$64 billion in revenue and $3.00–$3.15 EPS, signaling confidence in execution. Its cost-cutting program, expected to deliver $7.2 billion in savings by 2027, has already realized $4.5 billion. With operating margins rising back above 21% and free cash flow hitting $1.71 billion, Pfizer’s operational recovery appears stronger than investor sentiment suggests.

Metsera Deal Positions Pfizer In The Lucrative Obesity Market

Pfizer’s $10 billion acquisition of Metsera was not just a strategic move—it was a necessary transformation. The deal, completed in November 2025 after outbidding Novo Nordisk (NVO), grants Pfizer a portfolio of advanced GLP-1 and amylin analog candidates that can challenge Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy. Lead candidate MET-097i achieved a placebo-adjusted weight loss of 14.1% by week 28 in the VESPER-1 trial (NCT06712836), with a discontinuation rate of only 2.9%, demonstrating a superior safety profile compared to CagriSema, which recorded 8.4% discontinuation. Although the acquisition will be earnings-dilutive through 2030, the move mirrors Pfizer’s earlier success with Seagen, showing the company’s willingness to absorb short-term financial pain to secure long-term growth. By leveraging its global R&D and distribution scale, Pfizer is positioning itself as the next major entrant into the obesity therapeutics space, a segment forecast to exceed $100 billion annually by 2032.

Oncology Remains The Cornerstone Of Pfizer’s Growth

The Seagen integration continues to deliver tangible results. The PADCEV/Keytruda combination recently earned FDA approval as the first perioperative regimen for muscle-invasive bladder cancer, demonstrating a 60% reduction in disease recurrence risk and a 50% improvement in survival versus surgery alone. PADCEV alone is expected to exceed $3 billion in annual peak revenue. Meanwhile, Lorbrena sales surged 30.1% year-over-year to $268 million, and Pfizer’s oncology segment—driven by Abrysvo, Talzenna, and Genotropin—remains one of its highest-margin portfolios. The company expects to have at least eight oncology blockbusters by 2030, offsetting much of the revenue loss from the patent expirations of Eliquis, Ibrance, and Xtandi, which together represent about $18 billion in annual revenue at risk by 2027.

Core Portfolio Strength: Eliquis, Vyndaqel, And Cibinqo Deliver Stability

Pfizer’s core non-oncology products continue to underpin its earnings. The Vyndaqel family contributed $1.6 billion in Q3 2025 sales, while Eliquis, co-developed with Bristol Myers Squibb (NYSE:BMY), rose 24.6% year-over-year to $2.02 billion, with no meaningful erosion from the launch of Sandoz Apixaban SDZ (OTCQX:SDZNY) in Canada. Cibinqo, Nurtec/Vydura, and Inflectra generated more than $1 billion in combined quarterly sales. Additionally, biosimilars such as Abrilada, Retacrit, and Inflectra are giving Pfizer exposure to a market expected to reach $72 billion by 2035. These diversified revenue streams form a critical buffer as Pfizer transitions from COVID-driven profits to sustainable long-term growth.

Financial Discipline And Dividend Yield Anchor Investor Confidence

Pfizer continues to maintain one of the strongest dividend profiles among large-cap pharmaceutical firms. The stock offers a forward dividend yield of 6.69%, with a quarterly payout of $0.44 per share, amounting to around $2.4 billion in quarterly cash distributions. The dividend remains comfortably covered by $4.6 billion in operating cash flow, demonstrating resilience even amid acquisition-related costs. Free cash flow yield stands at 7.1%, while gross margin remains at 74.8%, higher than peers GSK and Bristol Myers Squibb. These numbers highlight Pfizer’s ability to sustain shareholder returns even during its transition phase.

Valuation Reflects Market Mispricing Rather Than Weak Fundamentals

Despite strong operational execution, Pfizer trades at depressed multiples: P/E 7.8x, EV/EBITDA 7.9x, and price-to-book 1.58x, all well below the healthcare sector’s median. Investors remain overly focused on the upcoming patent cliff and the Metsera acquisition’s dilution. Yet, by 2028, the combined revenue from oncology, obesity, and biosimilars could replace over $20 billion in lost sales. Short interest, which reached 127 million shares in October, has started to decline as institutional buying accelerates in the $24–$26 range. The technical floor around $20.90—set in April 2025—continues to act as a strong accumulation zone.

Risks Center On Patent Expiration And Pricing Reform

Pfizer’s largest near-term challenge remains the patent cliff between 2026 and 2028, with Eliquis, Xtandi, and Ibrance losing exclusivity. The introduction of TrumpRx, requiring global parity in drug pricing and direct-to-consumer discounts averaging 50%, threatens U.S. margins as 64% of Pfizer’s revenue originates domestically. Meanwhile, net debt has risen to $46.7 billion post-Metsera, reflecting increased acquisition leverage, though balance sheet health remains adequate due to strong free cash flow. Execution risk also lingers in integrating Seagen and Metsera—especially if Phase 3 GLP-1 results disappoint or regulatory timelines extend.

Technical Momentum Shows Base Formation Around $25

Technically, PFE trades in a consolidation band between $24.00–$26.40, forming a steady base above its 200-day moving average. A breakout above $27.00 could open an upside path toward $30.00, while downside protection remains near $22.00–$23.00. The stock’s price structure, combined with a 6.7% dividend yield, offers both income stability and long-term revaluation potential.

Pfizer’s Long-Term Outlook Combines Value, Cash Flow, And Innovation

Pfizer stands at a turning point where operational discipline meets pipeline potential. Its presence across oncology, biosimilars, vaccines, and now metabolic disease creates a diversified foundation few competitors can match. The market’s discounting of its future earnings provides investors a rare opportunity to capture both yield and growth. With cost synergies materializing, a solid pipeline advancing, and institutional support increasing, the company’s long-term upside remains substantial.

Verdict: Strong Buy — Target $32, Support $24, Resistance $30.

That's TradingNEWS